Clinical Trial

NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma

Study acronym: LauT1
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A single center, dose escalaion, Phase I clinical trial to demonstrate safety and efficacy of LauT-1, autologous "New York Esophageal Squamous Cell Carcinoma-1 T-Cell Receptor (NY-ESO-1 TCR)-directed T cells in combination with non-myeloablative (NMA) lymphodepleting chemotherapy and low dose irradiation (LDI) in patients with NY-ESO-1 positive sarcoma and melanoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-20; most recent amendment 2026-05-12.
Status change: Not Yet Recruiting → Recruiting 2025-04-16
Trial Details
NCT Number NCT06889766
Lead Sponsor Centre Hospitalier Universitaire Vaudois
Conditions Advanced Melanoma, Melanoma Metastatic, Sarcoma
Enrollment 9 participants
Start Date 2025-03-24
Primary Completion 2029-06 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-15